Recruiting PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT06085716

Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers

Sponsor: M.D. Anderson Cancer Center

Interventions Open Label Placebo Psychoeducational Intervention Psychoeducational Intervention+Placebo

Updated 7 times since 2023 Last updated: Oct 17, 2025 Started: Feb 16, 2024 Primary completion: Aug 31, 2027 Completion: Aug 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Fatigue and Metastatic Cancers and is currently actively recruiting participants. M.D. Anderson Cancer Center leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Nov 2025 — Present [monthly]

Recruiting PHASE2/PHASE3
May 2025 — Nov 2025 [monthly]

Recruiting PHASE2/PHASE3
Feb 2025 — May 2025 [monthly]

Recruiting PHASE2/PHASE3
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3

▶ Show 2 earlier versions

May 2024 — Jul 2024 [monthly]

Recruiting PHASE2_PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2023 — May 2024 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States